I agree that this site is using cookies. You can find further informations here.
X
Subbiah, V
449  results:
Search for persons X
?
1

63P Activity and safety of FGFR inhibitors in pan-cancer pa..:

Grochot, R.M. ; Joshi, K. ; Sathanantham, G....
ESMO Open.  9 (2024)  - p. 102292 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Welcoming the future: embracing novel technologies for a pr..:

Horgan, D. ; Hofman, P. ; Subbiah, V.
ESMO Open.  9 (2024)  8 - p. 103656 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Open-label, dose-escalation FIGHT-101 study of pemigatinib ..:

Saleh, M. ; Barve, M. ; Subbiah, V....
ESMO Open.  9 (2024)  7 - p. 103625 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Everolimus in combination with vandetanib in children, adol..:

Phadnis, S. ; Wang, X. ; Daw, N.C....
ESMO Open.  8 (2023)  6 - p. 101609 , 2023
Link: https://doi.org/10.1016/..
 
?
5

82TiP A modular, open-label, phase I/II study to evaluate t..:

Gianoukakis, A.G. ; Arnold, S.M. ; Kahn, S.A....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S87-S88 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Cracking KRASG12C across all solid tumors: the new kid on t..:

Bhamidipati, D. ; Subbiah, V.
ESMO Open.  8 (2023)  4 - p. 101591 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Sodium fluoride (Na18F) PET Response Criteria in Solid Tumo..:

Kairemo, K. ; Gouda, M.A. ; Buschhorn, L....
ESMO Open.  8 (2023)  4 - p. 101575 , 2023
Link: https://doi.org/10.1016/..
 
?
8

PP01.50 EMERGE-201: Phase 2 Basket Study of Lurbinectedin M..:

Spigel, D. ; Galsky, M.D. ; Heeke, A.L....
Journal of Thoracic Oncology.  18 (2023)  3 - p. e31 , 2023
Link: https://doi.org/10.1016/..
 
?
9

Precision oncology for BRAF-mutant cancers with BRAF and ME..:

Gouda, M.A. ; Subbiah, V.
ESMO Open.  8 (2023)  2 - p. 100788 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Cancer: slaying the nine-headed Hydra:

Adashek, J.J. ; Subbiah, V. ; Westphalen, C.B....
Annals of Oncology.  34 (2023)  1 - p. 61-69 , 2023
Link: https://doi.org/10.1016/..
 
?
11

EP13.07-06 Efficacy of Platinum Given after Lurbinectedin i..:

Trigo, J.M. ; Besse, B. ; Zaman, K....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S708-S709 , 2023
Link: https://doi.org/10.1016/..
 
?
12

EP08.02-081 Cabozantinib Plus Atezolizumab in First or Seco..:

Neal, J.W. ; Lim, F.L. ; Aix, S.P....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S439 , 2022
Link: https://doi.org/10.1016/..
 
?
13

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V. ; Pistilli, B. ; Braña, I....
ESMO Open.  7 (2022)  5 - p. 100571 , 2022
Link: https://doi.org/10.1016/..
 
?
14

NCI10329: Phase Ib Sequential Trial of Agents against DNA R..:

Yap, T.A. ; Ngoi, N. ; Dumbrava, E.E....
European Journal of Cancer.  174 (2022)  - p. S7 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Identifying FGFR2 fusions/rearrangements in cholangiocarcin..:

Schram, A. ; Borad, M. ; Sahai, V....
European Journal of Cancer.  174 (2022)  - p. S116 , 2022
Link: https://doi.org/10.1016/..
 
1-15